Atea Pharmaceuticals (AVIR) Accumulated Depreciation (2019 - 2025)

Atea Pharmaceuticals' Accumulated Depreciation history runs 7 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 37.65% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $1.5 million (up 37.65% YoY), while the FY2025 annual figure was $1.5 million, up 37.65% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $1.5 million, up from $1.1 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $1.5 million in Q4 2025, with the low at $161000.0 in Q4 2021.
• The 5-year median for Accumulated Depreciation is $689000.0 (2023), against an average of $749800.0.
• The sharpest annual moves came in 2021 and 2023: Accumulated Depreciation rose 21.97% in 2021, then jumped 152.38% in 2023.
• Atea Pharmaceuticals' Accumulated Depreciation stood at $161000.0 in 2021, then soared by 69.57% to $273000.0 in 2022, then surged by 152.38% to $689000.0 in 2023, then surged by 60.38% to $1.1 million in 2024, then surged by 37.65% to $1.5 million in 2025.
• Business Quant data shows AVIR's Accumulated Depreciation at $1.5 million in Q4 2025, $1.1 million in Q4 2024, and $689000.0 in Q4 2023.